HSP90-rich EVs are released by metastatic cancer cells, whereas small interfering RNA (siRNA) double-targeting HSP90α and HSP90β mRNAs efficiently decrease cancer cell viability, indicating a novel concept of HSP90 mRNA-targeted oligonucleotide therapeutics [1]. Here, HSP90AA1 is linked to metastatic malignant neoplasm.